Patents by Inventor Soren Padkjaer

Soren Padkjaer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Humanized antibodies against human interferon-alpha
    Patent number: 8658771
    Abstract: The present invention provides humanized anti-human IFN-? monoclonal antibodies useful for therapeutic applications in humans. Preferred antibodies are humanized versions of murine antibodies ACO-1 and ACO-2, as well as variants thereof.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: February 25, 2014
    Assignee: Argos Therapeutics, Inc.
    Inventors: Lars Anders Svensson, Soren Padkjaer, Birgitte Friedrichsen, Berit Olsen Krogh, Inger Lund Pedersen, Jan Fleckner
  • Humanized Antibodies Against Human Interferon-Alpha
    Publication number: 20130101602
    Abstract: The present invention provides humanized anti-human IFN-? monoclonal antibodies useful for therapeutic applications in humans. Preferred antibodies are humanized versions of murine antibodies ACO-1 and ACO-2, as well as variants thereof.
    Type: Application
    Filed: December 19, 2012
    Publication date: April 25, 2013
    Applicant: ARGOS THERAPEUTICS, INC.
    Inventors: Lars Anders Svensson, Soren Padkjaer, Birgitte Friedrichsen, Berit Olsen Krogh, Inger Lund Pedersen
  • Humanized antibodies against human interferon-alpha
    Patent number: 8361463
    Abstract: The present invention provides humanized anti-human IFN-? monoclonal antibodies useful for therapeutic applications in humans. Preferred antibodies are humanized versions of murine antibodies ACO-1 and ACO-2, as well as variants thereof.
    Type: Grant
    Filed: February 1, 2012
    Date of Patent: January 29, 2013
    Assignee: Argos Therapeutics, Inc.
    Inventors: Lars Anders Svensson, Soren Padkjaer, Birgitte Friedrichsen, Berit Olsen Krogh, Inger Lund Pedersen
  • Humanized Antibodies Against Human Interferon-Alpha
    Publication number: 20120195888
    Abstract: The present invention provides humanized anti-human IFN-? monoclonal antibodies useful for therapeutic applications in humans. Preferred antibodies are humanized versions of murine antibodies ACO-1 and ACO-2, as well as variants thereof.
    Type: Application
    Filed: February 1, 2012
    Publication date: August 2, 2012
    Applicant: NOVO NORDISK A/S
    Inventors: Lars Anders Svensson, Soren Padkjaer, Birgitte Friedrichsen, Berit Olsen Krogh, Inger Lund Pedersen
  • Humanized antibodies against human interferon-alpha
    Patent number: 8163885
    Abstract: The present invention provides humanized anti-human IFN-? monoclonal antibodies useful for therapeutic applications in humans. Preferred antibodies are humanized versions of murine antibodies ACO-1 and ACO-2, as well as variants thereof.
    Type: Grant
    Filed: May 6, 2009
    Date of Patent: April 24, 2012
    Assignee: Argos Therapeutics, Inc.
    Inventors: Lars Anders Svensson, Soren Padkjaer, Birgitte Friedrichsen, Berit Olsen Krogh, Inger Lund Pedersen
  • Humanized Antibodies Against Human Interferon-Alpha
    Publication number: 20110213125
    Abstract: The present invention provides humanized anti-human IFN-? monoclonal antibodies useful for therapeutic applications in humans. Preferred antibodies are humanized versions of murine antibodies ACO-1 and ACO-2, as well as variants thereof.
    Type: Application
    Filed: May 6, 2009
    Publication date: September 1, 2011
    Applicant: Novo Nordisk A/S
    Inventors: Lars Anders Svensson, Soren Padkjaer, Birgitte Friedrichsen, Berit Olsen Krogh, Inger Lund Pedersen
  • Compositions and methods for regulating NK cell activity
    Publication number: 20090191213
    Abstract: The present invention relates to novel compositions and methods for regulating an immune response in a subject. More particularly, the invention relates to specific antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects. The invention also relates to fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly in therapy, to increase NK cell activity or cytotoxicity in subjects.
    Type: Application
    Filed: January 3, 2006
    Publication date: July 30, 2009
    Applicant: Novo Nordisk A/S
    Inventors: Soren Padkjaer, Alessandro Moretta, Mariella Della Chiesa, Pascale Andre, Laurent Gauthier, Peter Reumert Wagtmann
  • Compositions and methods for regulating NK cell activity
    Publication number: 20060280740
    Abstract: The present invention relates to novel compositions and methods for regulating an immune response in a subject. More particularly, the invention relates to specific antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects. The invention also relates to fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly in therapy, to increase NK cell activity or cytotoxicity in subjects.
    Type: Application
    Filed: January 3, 2006
    Publication date: December 14, 2006
    Applicant: Novo Nordisk A/S
    Inventors: Soren Padkjaer, Alessandro Moretta, Mariella Della Chiesa, Pascale Andre, Laurent Gauthier, Peter Reumert Wagtmann